One of the most significant shifts in bioprocessing in 2025 is the rapid transition from traditional recirculating TFF to Single-Pass Tangential Flow Filtration (SPTFF). An updated Tangential Flow Filtration Market Trend report notes that SPTFF is gaining traction because it allows for continuous concentration and diafiltration in a single pass, eliminating the need for large recirculation tanks. This technology is essential for the industry’s broader move toward "Continuous Manufacturing," where raw materials are processed into final products without the interruptions inherent in batch-mode production.

In 2025, SPTFF is proving particularly valuable for the production of Viral Vectors and mRNA vaccines. These sensitive modalities often degrade when subjected to the high-shear forces and long processing times of traditional TFF. By using SPTFF, manufacturers can reduce the "hold-up volume" and processing time by up to 30%, ensuring higher product stability and potency. This breakthrough is a key factor in the Vaccine and Viral Vector segment, which is projected to grow at a robust CAGR of 12.3% through 2034.

Moreover, the integration of "Next-Generation Membrane Materials" is improving SPTFF efficiency. In late 2024, manufacturers introduced asymmetric polyethersulfone (PES) membranes with modified surface charges that resist fouling and provide 2x higher flux rates compared to standard materials. These innovations are allowing facilities to process larger volumes with smaller equipment footprints, making them ideal for the "Modular Cleanrooms" that are becoming popular in the biopharmaceutical sector. As we move toward 2030, SPTFF is expected to transition from an "innovation" to a "standard requirement" for high-volume biologics production.

FAQ: What is Single-Pass TFF (SPTFF)? Ans: It is a filtration method where the fluid passes through the filter once to reach its target concentration, rather than recirculating multiple times. This is faster and gentler on sensitive drugs.

Related Reports